<DOC>
	<DOC>NCT02564497</DOC>
	<brief_summary>The purpose of the study is to compare the Pharmacokinetics (PK) of Process E belatacept relative to Process C belatacept in Healthy subjects</brief_summary>
	<brief_title>A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>1. Signed Informed Consent 2. Target population: Healthy males and females. 3. Males and females, ages 18 to 55 years, inclusive. 4. Women of child bearing potential (WOCBP) with negative serum or urine pregnancy test 5. Women must not be breastfeeding 6. Men and WOCBP must agree to follow instructions for contraception 1. History of TB, malignancy, any other chronic or acute infecton or disease. 2. History of acute or chronic medical illness 3. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population. 4. History of allergy to belatacept or related compounds</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>